Find a TenderAwarded without competition

Published 30 Jan 2024, 15:27 GMT

Official UK procurement notice

Compounded Aseptic Medicines · UK public procurement notice

Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) (NHS & healthcare)

Framework agreement4 lotsGoodsAward procedure without prior publication of a call for competition

Sectors: Medical Devices & Pharma (33) Delivery: Scotland (UKM)

Framework ceiling (notional)Value not publishedframework ceiling, not attributable revenue

Awarded 30 Jan 2024no call for competition

Lots 4see the lot list below

What is being bought4 lots · detail below

Published requirement description

This Framework Agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags to NHS Scotland.

CPV: Pharmaceutical products

Lots and requirements (4)Procurement structure

4 lots · no lot values published

Lot #1Compounded Aseptic Medicines

Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses,

Atezolizumab

Cetuximab

Doxorubicin

Epirubicin

Infliximab (Inflectra®), (Remicade®), (Remsima®)

Nivolumab

Pembrolizumab

Pertuzumab

The Authority intends to awarded all presentations within this Lot to a single supplier.

Delivery: Scotland · All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

33600000 Pharmaceutical products

Lot #2Compounded Aseptic Medicines

Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses,

Cyclophosphamide

Fluorouracil

Irinotecan

Methotrexate

Rituximab (Mabthera®), (Rixathon®), (Truxima®)

The Authority intends to awarded all presentations within this Lot to a single supplier.

Delivery: Scotland · All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

33600000 Pharmaceutical products

Lot #3Compounded Aseptic Medicines

Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses,

Bortezomib

Carboplatin

Cisplatin

Docetaxel

Gemcitabine

Oxaliplatin

Trastuzumab (Herceptin®), (Herzuma®)

Vincristine

The Authority intends to awarded all presentations within this Lot to a single supplier.

33600000 Pharmaceutical products

Lot #4Compounded Aseptic Medicines - All Other Presentations

upply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses,

The molecules included in this Lot are,

Bevacizumab

Cytarabine

Infliximab (Zessly®)

Insulin

Methotrexate

Natalizumab

Nivolumab

Paclitaxel

Pemetrexed

Tocilizumab

Trastuzumab (Kanjinti®), (Ontruzant®)

Trastuzumab Subcutaneous

Vedolizumab

Each product line will be treated as an individual Lot and awarded as an unranked multi-supplier framework.

33600000 Pharmaceutical products

Procedure terms & legal framework

From the official record · publisher note attached

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Framework agreement
Who may use this agreement: Not stated in the notice; call-off rights may be limited to the establishing authority
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 30 Jan 2024, 15:27 GMT
Last source update: 30 Jan 2024, 15:27 GMT
Authority reference: NP38619
FTS notice number: 2024/S 000-003092
Classification (CPV): Pharmaceutical products
Delivery area: Scotland (UKM)
Official registry OCID: ocds-h6vhtk-0435c1 Find a Tender

Why no open competition: The procurement falls outside the scope of application of the directive
Published justification: This VEAT notice is to advise the need for modification to meet the additional demands of the Scottish Health and Social Care sector during the current Covid-19 pandemic and to maintain necessary supply due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015

Review and risk notes

Review procedure: The notification will incorporate a ‘standstill period’ of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the VEAT notice and the date on which the Authority proposes to conclude the relevant framework agreement.
The bringing of court proceedings against the authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer.
The bringing of court proceedings against the authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.

Publisher note: The estimated value(s) of the Framework Agreement referred to in Section V.2.4 (comprising three (3) Lots) cover(s) the twelve (12) month duration of the proposed modification period of the Framework Agreement. (SC Ref:756349)

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast

Suppliers appointed 3admitted to the panel · see the list ↓

Contracts signed 4latest 30 Jan 2024

4 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.

Contracts

Compounded Aseptic Medicines
Signed
30 Jan 2024
Value
£1,012,575
Status
active
Compounded Aseptic Medicines
Signed
30 Jan 2024
Value
£945,623
Status
active
Compounded Aseptic Medicines - All Other Presentations
Signed
30 Jan 2024
Value
£3,956,458
Status
active
Compounded Aseptic Medicines
Signed
30 Jan 2024
Value
£15,384,611
Status
active

Contracting authority & participating public bodies

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

Contracting authorityNHS & healthcareBody governed by public lawHealth Gyle Square (NSS Head Office), 1 South Gyle Crescent, Edinburgh, Scotland, EH12 9EBContact name, email

Dispute resolution & review bodies

Sheriff Court HouseReview body EdinburghContact email, phone

Framework contractors & participating bidders

3 commercial parties on the notice

Baxter Healthcare LtdFramework contractor Wallingford Road, Compton,, Newbury, Berkshire, UK, RG20 7QWContact phone
ITH Pharma LimitedFramework contractor Unit 4 Premier Park, Premier Park Road, London, UK, NW10 7NZContact phone
Qualasept Limited t/a Bath ASUFramework contractor Unit A15 Fiveways Light Industrial Estate, Westwells Road,, Corsham, UK, SN13 9RG

Official documents & specifications

Official links; attachments are not copied

No document links were published on the notice.